Skip to content
Altius – Lifestyle
Author:
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor “What This Means” Segment
June 8, 2026
Hugel highlights global vision for K-aesthetics
May 22, 2026
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress
May 20, 2026
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
May 14, 2026
Hugel reports record Q1 earnings, driving strong global growth in aesthetics
May 8, 2026
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
May 4, 2026
Hugel to enter ECM-based injectable market with aesthetic portfolio expansion
April 1, 2026
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
March 11, 2026